Literature DB >> 8707262

Expressions of basic fibroblast growth factor and its receptors and their relationship to proliferation of human hepatocellular carcinoma cell lines.

S Ogasawara1, H Yano, A Iemura, T Hisaka, M Kojiro.   

Abstract

On six human hepatocellular carcinoma (HCC) cell lines (KIM-1, KYN-1, KYN-2, KYN-3, HAK-1A, and HAK- 1B), we examined expressions and functions of the proteins and messenger RNAs (mRNAs) of basic fibroblast growth factor (bFGF) and its receptor, i.e., fibroblast growth factor receptor-1 (FGFR-1), as well as mRNA expressions of FGFR-2 approximately 4. All six cell lines expressed the proteins and mRNAs of bFGF and FGFR-1, and at least one of FGFR-2 approximately 4 mRNAs. Two of the six cell lines (KYN-1 and KYN-3) presented significant release of bFGF in culture supernatant, while the release in the remaining four cell lines was quite small. Addition of anti-bFGF neutralizing antibody (1, 10, or 20 microg/mL) to culture medium resulted in marked suppression of cell proliferation in all cell lines except HAK-1A. On the other hand, addition of exogenous bFGF (0.1, 1, or 5 ng/mL) to culture medium stimulated cell proliferation except in KIM-1 and KYN-2. When KIM-1 was transplanted to nude mice and anti-bFGF antibody was injected subcutaneously to a space surrounding the developed tumor, tumor proliferation was significantly suppressed in nude mice that received anti-bFGF antibody than in control mice, but there were no histological differences between the groups, including blood space formation in the stroma. In conclusion, hepatocellular carcinoma (HCC) cells may possess a proliferation mechanism regulated by an autocrine mechanism, a paracrine mechanism, or both, which are mediated by bFGF/FGFR.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8707262     DOI: 10.1053/jhep.1996.v24.pm0008707262

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  23 in total

Review 1.  Current status of molecularly targeted therapy for hepatocellular carcinoma: clinical practice.

Authors:  Masatoshi Kudo
Journal:  Int J Clin Oncol       Date:  2010-05-28       Impact factor: 3.402

Review 2.  Current status and perspective of antiangiogenic therapy for cancer: hepatocellular carcinoma.

Authors:  Shinji Tanaka; Shigeki Arii
Journal:  Int J Clin Oncol       Date:  2006-04       Impact factor: 3.402

3.  (125)I-labeled anti-bFGF monoclonal antibody inhibits growth of hepatocellular carcinoma.

Authors:  Peng-Hui Hu; Lan-Hong Pan; Patrick Ting-Yat Wong; Wen-Hui Chen; Yan-Qing Yang; Hong Wang; Jun-Jian Xiang; Meng Xu
Journal:  World J Gastroenterol       Date:  2016-06-07       Impact factor: 5.742

Review 4.  Signaling pathway/molecular targets and new targeted agents under development in hepatocellular carcinoma.

Authors:  Masatoshi Kudo
Journal:  World J Gastroenterol       Date:  2012-11-14       Impact factor: 5.742

5.  Transcriptional Induction of Periostin by a Sulfatase 2-TGFβ1-SMAD Signaling Axis Mediates Tumor Angiogenesis in Hepatocellular Carcinoma.

Authors:  Gang Chen; Ikuo Nakamura; Renumathy Dhanasekaran; Eriko Iguchi; Ezequiel J Tolosa; Paola A Romecin; Renzo E Vera; Luciana L Almada; Alexander G Miamen; Roongruedee Chaiteerakij; Mengtao Zhou; Michael K Asiedu; Catherine D Moser; Shaoshan Han; Chunling Hu; Bubu A Banini; Abdul M Oseini; Yichun Chen; Yong Fang; Dongye Yang; Hassan M Shaleh; Shaoqing Wang; Dehai Wu; Tao Song; Ju-Seog Lee; Snorri S Thorgeirsson; Eric Chevet; Vijay H Shah; Martin E Fernandez-Zapico; Lewis R Roberts
Journal:  Cancer Res       Date:  2016-11-21       Impact factor: 12.701

Review 6.  Locoregional and systemic therapy for hepatocellular carcinoma.

Authors:  Olumide B Gbolahan; Michael A Schacht; Eric W Beckley; Thomas P LaRoche; Bert H O'Neil; Maximilian Pyko
Journal:  J Gastrointest Oncol       Date:  2017-04

Review 7.  Heparanase and hepatocellular carcinoma: promoter or inhibitor?

Authors:  Shuo Dong; Xiong-Zhi Wu
Journal:  World J Gastroenterol       Date:  2010-01-21       Impact factor: 5.742

Review 8.  Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer.

Authors:  Michael Höpfner; Detlef Schuppan; Hans Scherübl
Journal:  World J Gastroenterol       Date:  2008-01-07       Impact factor: 5.742

9.  Expression of fibroblast growth factor receptor genes in human hepatoma-derived cell lines.

Authors:  Nobuyuki Asada; Yoshiharu Tanaka; Yasutaka Hayashido; Shigeaki Toratani; Mikio Kan; Mikiya Kitamoto; Toshio Nakanishi; Goro Kajiyama; Kazuaki Chayama; Tetsuji Okamoto
Journal:  In Vitro Cell Dev Biol Anim       Date:  2003 Jul-Aug       Impact factor: 2.416

10.  Evolving therapies in the treatment of hepatocellular carcinoma.

Authors:  Hans Christian Spangenberg; Robert Thimme; Hubert E Blum
Journal:  Biologics       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.